~~<i id='EAC3E6BC71'><strike id='EAC3E6BC71'><tt id='EAC3E6BC71'><pre id='EAC3E6BC71'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

hotspot

author：knowledge 2025-08-12 09:11:10 - browse：42641

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： How Vertex's cystic fibrosis drug is changing patients' lives

hotspot

knowledge

focus

hotspot

HealthworkersatalabinHongKongtestingforcoronavirusinMarch2022.KinCheung/APThewhollysyntheticmRNAvacc

WSS

How Vertex's cystic fibrosis drug is changing patients' lives

Hearing on Medicare drug price negotiation gets unusually heated

FDA panel to weigh approval of NurOwn, controversial ALS drug

Biotech stock slump in 2023: awaiting the turnaround

Experts study whether long Covid risk adds up with each reinfection

Biotech stock slump in 2023: awaiting the turnaround

focus

hotspot

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Senate HELP committee spars over health care workforce policies

After affirmative action ruling, medical educators look to 'holistic review'

What health policies could hitch a ride on a spending bill?

Medical records are filled with copy

NIH chief: government has fallen behind pharma on clinical trials

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

United colonoscopy coverage change 'may cost lives,' doctors say

Healthy food access boosts outcomes in two studies

hotspot

CDC's new outbreak response network to include Northeastern

Microbiome research is starting to find links to chronic diseases

Ohio still needs to do more to protect the right to abortion

Healthy food access boosts outcomes in two studies

Biotech lab space demand falls sharply

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

knowledge

focus

hotspot

hotspot